查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1406663

腎臟生物標記市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按產品類型、技術、最終用戶、地區和競爭細分

Renal Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product Type, By Technique, By End user, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年，全球腎臟生物標記市場價值為 13.1 億美元，預計在預測期內將出現令人印象深刻的成長，到 2028 年複合CAGR為7.25%。近年來，在患病率不斷上升的在推動下，全球腎臟生物標記市場出現了顯著成長腎臟疾病的發生率以及對早期疾病檢測和管理的需求不斷成長。腎臟生物標記在診斷和監測各種腎臟相關疾病中發揮著至關重要的作用，使其成為醫療保健領域的寶貴工具。腎臟生物標記是在血液、尿液或其他體液中發現的分子或物質，提供有關腎臟狀態和功能的有價值的資訊。這些生物標記可以幫助醫療保健專業人員在早期階段檢測腎臟疾病，評估腎損傷的嚴重程度並監測治療的有效性。常見的腎臟生物標記包括血清肌酸酐、尿液白蛋白和估計腎小球濾過率 (eGFR)。

慢性腎臟病（CKD）和其他腎臟相關疾病（例如急性腎損傷（AKI）和糖尿病腎病變）的盛行率不斷增加，是腎臟生物標記市場的主要驅動力。人口老化和全球糖尿病流行加劇了腎臟疾病負擔。早期診斷和介入對於有效管理腎臟疾病至關重要。腎臟生物標記提供了一種非侵入性且方便的診斷和監測腎臟疾病的方法，使其成為醫療保健提供者不可或缺的工具。技術的進步導致了更靈敏和特異的腎臟生物標記檢測的發展。新型生物標記和改進的檢測方法正在提高腎臟疾病診斷和預後的準確性。個人化醫療的趨勢也正在影響腎臟生物標記市場。基於患者獨特的生物標記特徵的客製化治療計劃變得越來越普遍，從而改善了腎臟疾病的整體管理。

主要市場促進因素

市場概況
預測期 2024-2028
2022 年市場規模 13.1億美元
2028 年市場規模 19.8億美元
2023-2028 年CAGR 7.25%
成長最快的細分市場 醫院和診所
最大的市場 北美洲

腎臟疾病盛行率的上升正在推動全球腎臟生物標記市場

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：全球腎臟生物標記市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型（功能性生物標記、血清肌酸酐、血清胱抑素C、尿液白蛋白、上調蛋白、嗜中性球明膠酶相關脂質運載蛋白(NGAL)、腎損傷分子-1、INTERLEUKIN-18 、其他）
    • 依技術分類（酵素連結免疫吸附分析 (ELISA)、顆粒增強比濁免疫分析 (PETIA)、比色分析、化學發光酶免疫分析 (CLIA)、液相層析質譜分析 (LC-MS)）
    • 按最終使用者（醫院和診所、診斷實驗室、其他）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖
    • 依產品類型
    • 依技術
    • 按最終用戶
    • 按地區

第 5 章：亞太地區腎臟生物標記市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 依技術
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國腎臟生物標記
    • 印度腎臟生物標記
    • 澳洲腎臟生物標記
    • 日本腎臟生物標記
    • 韓國腎臟生物標記

第 6 章：歐洲腎臟生物標記市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 依技術
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 7 章：北美腎臟生物標記市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 依技術
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 8 章：南美洲腎臟生物標記市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 依技術
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 9 章：中東和非洲腎臟生物標記市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品類型
    • 依技術
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非腎臟生物標記
    • 沙烏地阿拉伯腎臟生物標記
    • 阿拉伯聯合大公國腎臟生物標記
    • 埃及腎臟生物標記

第 10 章：市場動態

  • 促進要素
  • 挑戰

第 11 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 12 章：全球腎臟生物標記市場：SWOT 分析

第 13 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • 雅培實驗室
    • Business Overview
    • Company Snapshot
    • Product & Services
    • Current Capacity Analysis
    • Financials (In case of listed)
    • Recent Developments
    • SWOT Analysis
  • 貝克曼庫爾特公司（丹納赫公司）
  • 生物梅里埃公司
  • 比奧波爾圖公司
  • Bio-Rad 實驗室公司
  • 恩佐生物化學公司
  • F.霍夫曼-拉羅氏股份公司
  • 珀金埃爾默公司
  • 朗道實驗室有限公司
  • 西門子公司
  • 賽默飛世爾科技公司

第 15 章：策略建議

第 16 章：關於我們與免責聲明

簡介目錄
Product Code: 20081

Global Renal Biomarkers Market has valued at USD 1.31 Billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.25% through 2028. The global renal biomarkers market has witnessed significant growth in recent years, driven by an increasing prevalence of kidney diseases and a growing demand for early disease detection and management. Renal biomarkers play a crucial role in diagnosing and monitoring various kidney-related disorders, making them invaluable tools in the field of healthcare. Renal biomarkers are molecules or substances that are found in the blood, urine, or other bodily fluids and provide valuable information about the status and function of the kidneys. These biomarkers can help healthcare professionals detect kidney diseases at an early stage, assess the severity of kidney injury, and monitor the effectiveness of treatment. Common renal biomarkers include serum creatinine, urinary albumin, and estimated glomerular filtration rate (eGFR).

The increasing prevalence of chronic kidney disease (CKD) and other kidney-related disorders, such as acute kidney injury (AKI) and diabetic nephropathy, is a primary driver of the renal biomarkers market. Aging populations and the global diabetes epidemic have contributed to the growing burden of kidney diseases. Early diagnosis and intervention are essential for managing kidney diseases effectively. Renal biomarkers provide a non-invasive and convenient means of diagnosing and monitoring kidney disorders, making them indispensable tools for healthcare providers. Advances in technology have led to the development of more sensitive and specific renal biomarker assays. Novel biomarkers and improved detection methods are enhancing the accuracy of kidney disease diagnosis and prognosis. The trend towards personalized medicine is also impacting the renal biomarkers market. Tailored treatment plans based on a patient's unique biomarker profile are becoming more common, improving the overall management of kidney diseases.

Key Market Drivers

Market Overview
Forecast Period2024-2028
Market Size 2022USD 1.31 Billion
Market Size 2028USD 1.98 Billion
CAGR 2023-20287.25%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

Rising Prevalence of Kidney Diseases is Driving the Global Renal Biomarkers Market

Kidney diseases are becoming increasingly prevalent worldwide, posing a significant healthcare challenge. These conditions can lead to severe health complications and, in some cases, even be life-threatening. The rising incidence of kidney diseases has prompted extensive research in the medical field, leading to the development and adoption of renal biomarkers. These biomarkers have played a crucial role in early diagnosis, monitoring, and treatment of kidney diseases, driving the global renal biomarkers market forward. Kidney diseases encompass a range of conditions affecting the vital organs responsible for filtering waste products and excess fluid from the blood, maintaining electrolyte balance, and producing hormones to regulate blood pressure and red blood cell production. Common kidney diseases include chronic kidney disease (CKD), acute kidney injury (AKI), kidney stones, and polycystic kidney disease (PKD).

The global prevalence of kidney diseases has been on the rise for several reasons. First and foremost is the increasing prevalence of risk factors such as diabetes, hypertension, and obesity. These conditions are known to be significant contributors to kidney disease development. Additionally, an aging population and lifestyle factors like smoking and poor dietary choices have added to the burden of kidney diseases. Inadequate awareness and late-stage diagnosis have exacerbated the problem. Kidney diseases often progress silently, with symptoms only becoming apparent in the advanced stages. Early detection is crucial for effective intervention and management, making renal biomarkers a vital tool in the fight against kidney diseases.

Renal biomarkers are measurable indicators, such as proteins or molecules found in bodily fluids, that provide valuable information about kidney function. These biomarkers help healthcare professionals in various aspects of kidney disease management. Biomarkers can detect kidney dysfunction before symptoms manifest, allowing for early intervention and improved outcomes. Renal biomarkers enable continuous monitoring of kidney function, helping doctors assess the progression of the disease and make necessary treatment adjustments.

Increased Drug Development and Clinical Trials is Driving the Global Renal Biomarkers Market

Renal biomarkers have become indispensable in the drug development process. They play a pivotal role in various phases of clinical trials, from patient selection and monitoring to assessing treatment efficacy and safety. Renal biomarkers help identify suitable participants for clinical trials by providing insights into the severity and stage of kidney disease. This ensures that the right patients are enrolled, improving trial accuracy and outcomes. During clinical trials, renal biomarkers are used to monitor how drugs impact kidney function. This allows researchers to assess the safety and efficacy of potential treatments. Renal biomarkers can help detect kidney-related adverse events in clinical trial participants, enabling prompt intervention and minimizing potential harm. Biomarker data can aid in the development of personalized treatment plans, allowing clinicians to tailor therapies to individual patients based on their specific kidney profiles.

Government agencies, pharmaceutical companies, and research organizations worldwide have recognized the importance of addressing kidney diseases. Consequently, there has been a surge in initiatives, collaborations, and investments aimed at advancing renal biomarker research. These endeavors are driving innovation and accelerating the development of novel diagnostics and therapeutics. As drug development and clinical trials continue to expand, the global renal biomarkers market is poised for significant growth. Emerging technologies, such as artificial intelligence and machine learning, are enhancing our ability to identify and validate novel biomarkers quickly. Additionally, the integration of multi-omics data (genomics, proteomics, metabolomics) is providing a more comprehensive understanding of kidney diseases, leading to the discovery of new biomarkers.

Key Market Challenges

Limited Biomarker Validation

One of the primary challenges facing the renal biomarkers market is the limited validation of biomarkers. The development of reliable and accurate renal biomarkers requires extensive research and clinical trials to establish their efficacy and specificity. The validation process is time-consuming and expensive, and many potential biomarkers do not meet the necessary criteria for clinical use. As a result, the market faces a shortage of well-validated biomarkers, hindering its growth potential.

Regulatory Hurdles

Regulatory approvals are essential for the commercialization of renal biomarkers. The regulatory pathway for biomarker approval can be complex and varies from one region to another. Meeting the stringent requirements of regulatory agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) can be a lengthy and costly process. Navigating these regulatory hurdles can delay the market entry of new biomarkers and increase the overall cost of product development.

Reimbursement Challenges

Reimbursement is a critical factor in the adoption of renal biomarkers in clinical practice. Healthcare providers and payers need to determine the cost-effectiveness of using biomarkers for renal disease diagnosis and management. Convincing payers to reimburse for these tests can be challenging, especially if the cost-benefit ratio is not clearly established. Demonstrating the long-term cost savings and improved patient outcomes associated with biomarker use is essential to overcome this hurdle.

Competition and Market Saturation

The renal biomarkers market is becoming increasingly competitive, with multiple companies and research institutions vying to develop and commercialize new biomarkers. As the number of players in the market grows, it becomes harder for individual biomarkers to stand out. Market saturation can also lead to price competition, potentially affecting the profitability of biomarker developers.

Data Privacy and Ethical Concerns

With the growing use of biomarkers, concerns about data privacy and ethical issues related to patient information and biological samples have come to the forefront. Maintaining patient confidentiality and ensuring that data is used responsibly is a significant challenge, especially as biomarker research often involves extensive data collection and analysis.

Clinical Utility and Physician Adoption

For renal biomarkers to gain widespread acceptance, they must demonstrate clear clinical utility and be adopted by healthcare professionals. Physicians may be resistant to change and hesitant to incorporate new biomarkers into their diagnostic and treatment algorithms, especially if they are unfamiliar with their use or if there is insufficient evidence of their clinical benefit.

Key Market Trends

Technological Advancements

The global healthcare landscape has witnessed remarkable transformations in recent years, driven by rapid technological advancements. One area that has benefited significantly from these innovations is the diagnosis and treatment of renal diseases. The Global Renal Biomarkers Market is experiencing substantial growth as cutting-edge technologies continue to reshape the way we understand, diagnose, and manage renal conditions. Renal biomarkers are playing a pivotal role in this evolution, enabling early detection, precise diagnosis, and personalized treatment plans.

The development of advanced diagnostic tools, such as mass spectrometry and next-generation sequencing, has revolutionized the identification of renal biomarkers. These technologies allow for the rapid and accurate analysis of biological samples, enabling the detection of even subtle changes in renal function. Data analytics and artificial intelligence (AI) have become integral to the analysis of renal biomarker data. AI algorithms can process vast amounts of patient data, identifying patterns and trends that may be missed by human clinicians. This enhances the accuracy of renal disease diagnosis and the prediction of disease progression. Technological advancements have enabled the move toward personalized medicine in the field of nephrology. Renal biomarkers are used to tailor treatment plans to individual patients, taking into account their unique genetic makeup and disease characteristics. This approach improves treatment outcomes and reduces the risk of adverse effects. Miniaturization and portable diagnostic devices have made it possible to perform renal biomarker testing at the point of care. This is particularly important in remote or underserved areas where access to centralized laboratories may be limited. Point-of-care testing allows for quicker diagnosis and treatment initiation.

Segmental Insights

Product Type Insights

Based on the category of Product Type, Serum Cystatin C emerged as the dominant player in the global market for Renal Biomarkers in 2022. erum Cystatin C is a small protein produced by all nucleated cells at a constant rate and is freely filtered by the glomerulus in the kidneys. Unlike other traditional biomarkers like serum creatinine, Serum Cystatin C is less influenced by factors such as age, gender, muscle mass, and diet, making it a more reliable marker of renal function. Serum Cystatin C is sensitive to changes in glomerular filtration rate (GFR), making it a valuable tool for the early detection of kidney dysfunction. It can detect renal impairment even when serum creatinine levels remain within the normal range. Unlike creatinine-based estimates of GFR, Serum Cystatin C offers better precision in estimating renal function, especially in patients with conditions affecting muscle mass or dietary habits. Serum Cystatin C levels show less day-to-day variability compared to creatinine, making it a more consistent marker for monitoring renal function over time. Research has shown that elevated Serum Cystatin C levels are associated with a higher risk of adverse outcomes in patients with renal diseases, including progression to end-stage renal disease and cardiovascular events.

End user Insights

The Hospitals & Clinics segment is projected to experience rapid growth during the forecast period. Hospitals and clinics are primary healthcare settings where patients seek medical care, including kidney-related issues. These institutions see a high volume of patients with diverse medical conditions, making them key locations for renal biomarker testing. This sheer patient access ensures a consistent demand for renal biomarkers. Hospitals, in particular, are equipped with advanced diagnostic laboratories and imaging equipment. This infrastructure enables healthcare professionals to conduct a wide range of tests, including renal biomarker assays, with precision and efficiency. This makes hospitals and clinics natural hubs for renal biomarker testing. Renal biomarkers are often used in conjunction with other diagnostic tools and tests. Hospitals and clinics offer a multidisciplinary approach to healthcare, bringing together specialists from various fields such as nephrology, cardiology, and endocrinology. This approach facilitates comprehensive patient evaluation and accurate diagnosis. Many hospitals are affiliated with research institutions and universities, which fosters a culture of innovation and continuous research in the medical field. This environment promotes the development of new renal biomarkers and the improvement of existing ones. The rising global prevalence of chronic diseases, including diabetes and hypertension, has led to a surge in kidney-related conditions. Hospitals and clinics are at the forefront of managing these chronic diseases, resulting in an increased need for renal biomarker testing.

Regional Insights

North America emerged as the dominant player in the global Renal Biomarkers market in 2022, holding the largest market share in terms of value. North America boasts a robust healthcare infrastructure, including world-renowned research institutions and pharmaceutical companies. This environment encourages continuous research and development efforts in the field of renal biomarkers. Leading academic institutions collaborate with industry players to develop innovative biomarkers, diagnostic tests, and treatment strategies. The United States, in particular, is at the forefront of technological advancements in healthcare. Advanced diagnostic tools, such as mass spectrometry and immunoassays, are widely available in North American laboratories, facilitating the detection and quantification of renal biomarkers with precision and accuracy. North America has well-established regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and Health Canada, which provide a clear pathway for biomarker approval and commercialization. Stringent regulatory oversight ensures that only high-quality and reliable biomarkers enter the market, instilling confidence in healthcare professionals and patients alike.

Key Market Players

Abbott Laboratories

Beckman Coulter Inc. (Danaher Corporation)

bioMerieux SA

BioPorto A/S

Bio-Rad Laboratories Inc.

Enzo Biochem Inc.

F. Hoffmann-La Roche AG

PerkinElmer Inc.

Randox Laboratories Ltd.

Siemens AG

Thermo Fisher Scientific Inc.

Report Scope:

In this report, the Global Renal Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Renal Biomarkers Market, By Product Type:

  • Functional Biomarker
  • Serum Creatinine
  • Serum Cystatin C
  • Urine Albumin
  • Up-regulated Protein
  • Neutrophil Gelatinase-Associated Lipocalin (NGAL)
  • Kidney Injury Molecule-1
  • INTERLEUKIN-18
  • Others

Renal Biomarkers Market, By Technique:

  • Enzyme-linked Immunosorbent Assay (ELISA)
  • Particle-enhanced Turbidimetric Immunoassay (PETIA)
  • Colorimetric Assay
  • Chemiluminescent Enzyme Immunoassay (CLIA)
  • Liquid Chromatography Mass Spectrometry (LC-MS)

Renal Biomarkers Market, By End user:

  • Hospitals & Clinics
  • Diagnostic Laboratory
  • Others

Renal Biomarkers Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Renal Biomarkers Market.

Available Customizations:

  • Global Renal Biomarkers market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Renal Biomarkers Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Product Type (Functional Biomarker, Serum Creatinine, Serum Cystatin C, Urine Albumin, Up-regulated Protein, Neutrophil Gelatinase-Associated Lipocalin (NGAL), Kidney Injury Molecule-1, INTERLEUKIN-18, Others)
    • 4.2.2. By Technique (Enzyme-linked Immunosorbent Assay (ELISA), Particle-enhanced Turbidimetric Immunoassay (PETIA), Colorimetric Assay, Chemiluminescent Enzyme Immunoassay (CLIA), Liquid Chromatography Mass Spectrometry (LC-MS))
    • 4.2.3. By End user (Hospitals & Clinics, Diagnostic Laboratory, Others)
    • 4.2.4. By Region
    • 4.2.5. By Company (2022)
  • 4.3. Market Map
    • 4.3.1. By Product Type
    • 4.3.2. By Technique
    • 4.3.3. By End user
    • 4.3.4. By Region

5. Asia Pacific Renal Biomarkers Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type
    • 5.2.2. By Technique
    • 5.2.3. By End user
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Renal Biomarkers Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Product Type
        • 5.3.1.2.2. By Technique
        • 5.3.1.2.3. By End user
    • 5.3.2. India Renal Biomarkers Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Product Type
        • 5.3.2.2.2. By Technique
        • 5.3.2.2.3. By End user
    • 5.3.3. Australia Renal Biomarkers Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Product Type
        • 5.3.3.2.2. By Technique
        • 5.3.3.2.3. By End user
    • 5.3.4. Japan Renal Biomarkers Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Product Type
        • 5.3.4.2.2. By Technique
        • 5.3.4.2.3. By End user
    • 5.3.5. South Korea Renal Biomarkers Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Product Type
        • 5.3.5.2.2. By Technique
        • 5.3.5.2.3. By End user

6. Europe Renal Biomarkers Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Technique
    • 6.2.3. By End user
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Renal Biomarkers Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Technique
        • 6.3.1.2.3. By End user
    • 6.3.2. Germany Renal Biomarkers Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Technique
        • 6.3.2.2.3. By End user
    • 6.3.3. Spain Renal Biomarkers Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Technique
        • 6.3.3.2.3. By End user
    • 6.3.4. Italy Renal Biomarkers Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Product Type
        • 6.3.4.2.2. By Technique
        • 6.3.4.2.3. By End user
    • 6.3.5. United Kingdom Renal Biomarkers Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Product Type
        • 6.3.5.2.2. By Technique
        • 6.3.5.2.3. By End user

7. North America Renal Biomarkers Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Technique
    • 7.2.3. By End user
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Renal Biomarkers Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Technique
        • 7.3.1.2.3. By End user
    • 7.3.2. Mexico Renal Biomarkers Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Technique
        • 7.3.2.2.3. By End user
    • 7.3.3. Canada Renal Biomarkers Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Technique
        • 7.3.3.2.3. By End user

8. South America Renal Biomarkers Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Technique
    • 8.2.3. By End user
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Renal Biomarkers Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Technique
        • 8.3.1.2.3. By End user
    • 8.3.2. Argentina Renal Biomarkers Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Technique
        • 8.3.2.2.3. By End user
    • 8.3.3. Colombia Renal Biomarkers Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Technique
        • 8.3.3.2.3. By End user

9. Middle East and Africa Renal Biomarkers Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Technique
    • 9.2.3. By End user
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Renal Biomarkers Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Technique
        • 9.3.1.2.3. By End user
    • 9.3.2. Saudi Arabia Renal Biomarkers Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Technique
        • 9.3.2.2.3. By End user
    • 9.3.3. UAE Renal Biomarkers Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Technique
        • 9.3.3.2.3. By End user
    • 9.3.4. Egypt Renal Biomarkers Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Product Type
        • 9.3.4.2.2. By Technique
        • 9.3.4.2.3. By End user

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Renal Biomarkers Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Abbott Laboratories
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Product & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. Beckman Coulter Inc. (Danaher Corporation)
  • 14.3. bioMerieux SA
  • 14.4. BioPorto A/S
  • 14.5. Bio-Rad Laboratories Inc.
  • 14.6. Enzo Biochem Inc.
  • 14.7. F. Hoffmann-La Roche AG
  • 14.8. PerkinElmer Inc.
  • 14.9. Randox Laboratories Ltd.
  • 14.10. Siemens AG
  • 14.11. Thermo Fisher Scientific Inc.

15. Strategic Recommendations

16. About Us & Disclaimer